Australian medical technology company LBT Innovations Limited has successfully sold its APAS® Independence instrument to pharmaceutical giant Bristol Myers Squibb in the United States. This landmark sale marks LBT's first foray into the US pharmaceutical market, signaling a significant expansion of its artificial intelligence-driven microbiology automation technology.
The sale, completed within an impressive three-month timeframe, comes as part of Bristol Myers Squibb's ongoing evaluation of the APAS® Independence, which began in the September 2024 quarter. This rapid progression from evaluation to purchase underscores the compelling value proposition of LBT's cutting-edge technology in the pharmaceutical industry.
Download the full press release here.
